Article info

Download PDFPDF

Original research
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials

Authors

  • Ian N Bruce Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal & Dermatological Sciences, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK PubMed articlesGoogle scholar articles
  • Ronald F van Vollenhoven Amsterdam Rheumatology Center ARC, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centre, Amsterdam (North Holland), The Netherlands PubMed articlesGoogle scholar articles
  • Konstantina Psachoulia Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Catharina Lindholm Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden PubMed articlesGoogle scholar articles
  • Emmanuelle Maho Biometrics, Statistics, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Raj Tummala Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Raj Tummala; Raj.Tummala{at}astrazeneca.com
View Full Text

Citation

Bruce IN, van Vollenhoven RF, Psachoulia K, et al
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials

Publication history

  • Received June 24, 2022
  • Accepted December 5, 2022
  • First published January 13, 2023.
Online issue publication 
January 13, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.